Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

Sponsored by:	European Organization for Research and Treatment of Cancer
Information provided:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00458913

Purpose:

RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with cisplatin may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects and how well giving bortezomib together with cisplatin works as first-line therapy in treating patients with malignant mesothelioma.

Condition	Intervention	Phase
Malignant Mesothelioma	Drug: bortezomib Drug: cisplatin	Phase 2

Eligibility

Study Design: Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment

Official Title: Phase II Study of Bortezomib (VELCADE) With Cisplatin as First Line Treatment of Malignant Mesothelioma

Enrollment Size: Both

Gender: 18 Years

Min. Age: N/A

Max. Age: No

Location and Contact Information

United Kingdom, England
Royal Marsden - Surrey, Sutton, England, SM2 5PT, United Kingdom
Status:

Last modified: July 29 2010.